Company intelligence / Profile preview

Hainan Huluwa Pharmaceutical Group Co., Ltd.

Ownership: Private
Employees: ~2080
Development stage: Other

Overview

The company has multiple commercialized pediatric medicines focused on digestive and respiratory systems. Several pipeline candidates are in advanced clinical phases targeting infectious diseases, chronic bronchitis, epilepsy, viral pneumonia, etc.

Therapeutic areas: PulmonologyWomen's HealthOtherGastroenterologyNeurologyInfectious Diseases
Modalities: Small molecule drugsHerbal medicinesChemical drugs
Industry: Biotech

Drug pipeline

8 assets

Xiao'er Feire Kechuan Granule

7 more assets in the full pipeline.

Partnerships

Strategic partnerships for distribution within China mentioned but no specific partner names disclosed publicly.

Beyond the preview

Go deeper on Hainan Huluwa Pharmaceutical Group Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hainan Huluwa Pharmaceutical Group Co., Ltd..